CTMX (CytomX Therapeutics) Forward Dividend Yield % : 0.00% (As of Mar. 22, 2025)

View and export this data going back to 2015. Start your Free Trial

What is CytomX Therapeutics Forward Dividend Yield %?

As of today (2025-03-22), the Forward Annual Dividend Yield of CytomX Therapeutics is 0.00%.

As of today (2025-03-22), the Trailing Annual Dividend Yield of CytomX Therapeutics is 0.00%.

CTMX's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.43
* Ranked among companies with meaningful Forward Dividend Yield % only.

CytomX Therapeutics's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of CytomX Therapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, CytomX Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Forward Dividend Yield % falls into.

CytomX Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

CytomX Therapeutics (NAS:CTMX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

CytomX Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (NAS:CTMX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Executives

Marcia Belvin	officer: SVP, Chief Scientific Officer	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Christopher Ogden	officer: SVP, Finance and Accounting	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Yu-waye Chu	officer: Chief Medical Officer	FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Lloyd A Rowland	officer: General Counsel	AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Sean A. Mccarthy	director, officer: President and CEO	343 OYSTER POINT BLVD., SUITE 100, SOUTH SAN FRANCISCO CA 94080
Jeffrey B Landau	officer: Chief Financial Officer	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Amy C. Peterson	officer: EVP, Chief Development Officer	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Carlos Campoy	officer: Chief Financial Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Alison L. Hannah	officer: Chief Medical Officer	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Alan Ashworth	director	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104